Search This Blog

Friday, February 27, 2026

Atrium Therapeutics launches after Avidity spin-off, $270 million to advance RNA cardiomyopathy pipeline

 


  • Spin-off distribution from Avidity Biosciences triggered Atrium Therapeutics' trading debut today on Nasdaq under ticker RNA.
  • Transaction occurs amid Novartis’s acquisition of Avidity Biosciences, separating Atrium’s RNA cardiomyopathy assets into a standalone company.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)